238,565 Shares in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Acquired by Wasatch Advisors LP

Wasatch Advisors LP purchased a new position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 238,565 shares of the company’s stock, valued at approximately $1,431,000. Wasatch Advisors LP owned 0.92% of Eton Pharmaceuticals as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in ETON. Nantahala Capital Management LLC bought a new stake in Eton Pharmaceuticals during the 2nd quarter worth approximately $3,095,000. Westside Investment Management Inc. increased its holdings in Eton Pharmaceuticals by 2.0% during the 2nd quarter. Westside Investment Management Inc. now owns 585,400 shares of the company’s stock worth $1,926,000 after purchasing an additional 11,440 shares in the last quarter. Aristides Capital LLC bought a new stake in Eton Pharmaceuticals during the 2nd quarter worth approximately $658,000. Thompson Siegel & Walmsley LLC bought a new stake in Eton Pharmaceuticals during the 2nd quarter worth approximately $420,000. Finally, Stonepine Capital Management LLC bought a new stake in Eton Pharmaceuticals during the 2nd quarter worth approximately $362,000. 27.86% of the stock is owned by institutional investors and hedge funds.

Eton Pharmaceuticals Trading Up 6.2 %

Eton Pharmaceuticals stock opened at $13.53 on Monday. The business’s 50 day simple moving average is $8.67 and its 200 day simple moving average is $5.55. Eton Pharmaceuticals, Inc. has a 12 month low of $3.03 and a 12 month high of $13.72. The company has a market cap of $349.62 million, a price-to-earnings ratio of -61.50 and a beta of 1.25.

Insider Activity

In other Eton Pharmaceuticals news, major shareholder Opaleye Management Inc. bought 57,500 shares of the stock in a transaction on Tuesday, September 10th. The shares were acquired at an average price of $4.65 per share, with a total value of $267,375.00. Following the acquisition, the insider now directly owns 2,660,000 shares of the company’s stock, valued at $12,369,000. The trade was a 2.21 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have bought 85,600 shares of company stock valued at $462,674 in the last 90 days. Insiders own 14.89% of the company’s stock.

Wall Street Analysts Forecast Growth

ETON has been the subject of several recent analyst reports. Craig Hallum upped their target price on Eton Pharmaceuticals from $10.00 to $15.00 and gave the company a “buy” rating in a report on Monday, October 28th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price (up from $11.00) on shares of Eton Pharmaceuticals in a report on Tuesday, November 26th.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.